For four decades, India has waged a quiet war against HIV — and by many measures, it has been winning. Yet as the country enters the sixth phase of its National AIDS Control Programme, the epidemic reveals itself not as a problem being solved but as one that is shifting shape: moving into new geographies, younger bodies, and communities where old strategies no longer reach. The transition to NACP Phase-VI is less a victory lap than a reckoning with the distance still to travel before 2030's promise of ending AIDS as a public health threat can be honestly claimed.
India's HIV/AIDS Fight Enters Critical Phase as Epidemic Evolves
Mother-to-child transmission remains at 10% in 2024, above the 5% elimination threshold, affecting vulnerable newborns and families.
The virus has adapted. It affects those younger, is more dispersed.
Mark
The numbers sound remarkable—80% reduction in AIDS deaths, 97% viral suppression. Why does the piece insist we're not done?
Mimi
Because the epidemic has changed shape. The old strategy worked brilliantly for certain populations. But now the virus is spreading among younger people, through sexual networks, and in places like Punjab where drug use is driving exponential growth. The national average masks what's actually happening on the ground.
Mark
So the virus found new pathways.
Mimi
Exactly. And the old categories—the way we used to think about "key populations"—don't capture that anymore. A young person in a city with access to dating apps faces different risks than a person who injects drugs, but both are vulnerable in ways the previous programs didn't fully address.
Mark
What's the biggest obstacle to the new strategy?
Mimi
Stigma. It's mentioned almost as an afterthought, but it's the thing that keeps people from getting tested, from staying in treatment, from being honest about their risk. You can have the best drugs and the best surveillance systems, but if someone is terrified of being discovered, none of it reaches them.
Mark
And the mother-to-child transmission number—10% instead of 5%—that's still a lot of babies.
Mimi
It is. Hundreds every year. And it's preventable. The technology exists. What's missing is the reach—making sure every pregnant woman, no matter where she lives or what her circumstances are, actually gets screened and treated. That's the structural part. That's the hard part.
El Pulso
- India's HIV program has achieved what once seemed unthinkable — an 80% drop in AIDS deaths and 97% viral suppression among treated patients — yet the epidemic is quietly accelerating in northeastern states and Punjab, where injecting drug use is driving infection rates 40 times the national average.
- The virus has outgrown its old boundaries: new infections are increasingly spreading through casual and regular sexual partners, meaning HIV is no longer contained within defined 'key populations,' and roughly 2.25 crore young people enter peak vulnerability each year.
- Mother-to-child transmission, though dramatically reduced, still stands at 10% in 2024 — double the threshold required for elimination — leaving hundreds of newborns infected annually and exposing gaps in how care reaches pregnant women across geography and social margin.
- NACP Phase-VI responds with a four-pronged strategy: AI-driven vulnerability mapping to replace categorical risk labels, deeper integration with national health insurance and telemedicine, a hard push to eliminate vertical transmission by 2030, and a direct assault on the stigma that keeps people from seeking diagnosis and care.
- Public health officials are candid that the final stretch of any epidemic is its hardest — not a medical problem alone, but a social, behavioral, and structural one — and whether India can execute this ambitious vision at scale before the 2030 deadline remains genuinely uncertain.
For four decades, India has waged a quiet war against HIV — and by many measures, it has been winning. Yet as the country enters the sixth phase of its National AIDS Control Programme, the epidemic reveals itself not as a problem being solved but as one that is shifting shape: moving into new geographies, younger bodies, and communities where old strategies no longer reach. The transition to NACP Phase-VI is less a victory lap than a reckoning with the distance still to travel before 2030's promise of ending AIDS as a public health threat can be honestly claimed.
India has spent four decades constructing one of the world's most effective HIV prevention systems, and the results are real: new infections have fallen by nearly half since 2010, AIDS-related deaths have dropped by more than 80%, and viral suppression among people in treatment now exceeds 97%. The country has moved entirely to Dolutegravir-based regimens, placing it among global leaders in treatment outcomes.
But as India enters NACP Phase-VI — its HIV strategy for 2026 to 2031 — the epidemic is making clear it has not finished. The national prevalence figure of 0.20% conceals a more troubling picture: states like Assam, Tripura, Arunachal Pradesh, and Punjab are seeing rising infections driven by injecting drug use, with prevalence among that population running 40 times the national average. A single needle-sharing event carries roughly a one-in-160 chance of transmission — and when drug-use epidemics take hold, they can spiral with terrifying speed.
The character of new infections is also shifting. HIV is increasingly spreading through casual and regular sexual partners, signaling that the virus has moved beyond the populations that older prevention strategies were designed to reach. India's young people are especially exposed: roughly 2.25 crore adolescents enter the 15-to-25 age bracket each year, navigating digital environments that carry their own risks. And mother-to-child transmission, though reduced from over 25% in 2020 to 10% in 2024, still sits above the 5% threshold for elimination — meaning hundreds of newborns continue to acquire HIV from their mothers annually.
NACP-VI responds with four major shifts. The first replaces category-based targeting with a framework called Sampoorna Suraksha, using AI-driven self-risk assessments and virtual outreach to follow vulnerability wherever it appears. The second deepens early detection and treatment retention through integration with Ayushman Bharat and telemedicine. The third commits to eliminating mother-to-child transmission of HIV and syphilis by 2030, requiring that every pregnant woman — regardless of geography, income, or social status — be reached with screening and care. The fourth confronts stigma directly, recognizing that discrimination in homes, hospitals, and workplaces remains the most persistent driver of delayed diagnosis.
India's pharmaceutical and biotechnology sectors are positioned to support new tools, and the government's commitment appears firm. But officials acknowledge the hardest truth of epidemic control: the last mile is never purely medical. It is social, behavioral, and structural. Whether India can execute this vision at the scale and speed the 2030 deadline demands is the question that Phase-VI will have to answer.
India has spent four decades building one of the world's most effective HIV prevention and treatment systems. The numbers tell a story of genuine progress: new infections have fallen by nearly half since 2010, AIDS-related deaths have plummeted by more than 80%, and among people receiving treatment, viral suppression now exceeds 97%. The country has moved entirely to Dolutegravir-based drug regimens, placing it among global leaders in treatment outcomes. By any measure, the National AIDS and STD Control Programme has delivered results that seemed impossible a generation ago.
Yet as India enters the next phase of its HIV strategy—NACP Phase-VI, running from 2026 to 2031—officials and public health experts are sounding a different note. The epidemic, they say, is not finished. It is evolving. In some places, it is accelerating. The national HIV prevalence of 0.20% obscures a more complicated reality: emerging hotspots in states like Assam, Arunachal Pradesh, Tripura, and Punjab are reporting rising infection rates, driven largely by injecting drug use. Among people who inject drugs, HIV prevalence runs 40 times higher than the national average. A single needle-sharing event carries roughly a one-in-160 chance of transmission. When drug-use epidemics take hold, they can spiral with terrifying speed if not met with equally swift intervention.
The character of new infections is shifting in ways that complicate the old playbook. Increasingly, people are acquiring HIV from casual or regular sexual partners—a pattern that signals the virus is no longer confined to what public health officials call "key populations." India's young people remain particularly vulnerable. Each year, roughly 2.25 crore adolescents enter the 15-to-25 age bracket, a cohort with easy access to digital platforms and all the risky behaviors those platforms can enable. Meanwhile, mother-to-child transmission, though dramatically reduced from over 25% in 2020 to 10% in 2024, still sits above the 5% threshold considered necessary for true elimination. Hundreds of newborns continue to acquire HIV from their mothers each year.
The virus, in short, has adapted. It affects younger people. It is more geographically dispersed. It exploits vulnerabilities that the previous generation of prevention strategies did not fully anticipate. NACP-VI is being framed as India's most ambitious response yet—a strategy built on four major shifts in how the country approaches the epidemic.
The first shift moves away from targeting people by category and toward following vulnerability itself. Rather than organizing prevention around labels like "high-risk groups," the new framework—called Sampoorna Suraksha—will use artificial intelligence-driven self-risk assessments, virtual outreach, and newer pharmaceutical tools to reach vulnerable individuals wherever they are. Disease surveillance platforms will track hotspots and identify patterns of transmission in real time. The second shift deepens India's commitment to early detection and lifelong treatment retention. Linkages with Ayushman Bharat, the government's health insurance scheme, and integration with telemedicine will help overcome the barriers that currently prevent people from staying in care. The third shift targets the elimination of vertical transmission—the passing of HIV and syphilis from mother to child—by 2030, requiring that every pregnant woman, regardless of geography, caste, income, or marital status, be reached with screening and treatment. The fourth addresses stigma directly, acknowledging that discrimination in homes, hospitals, workplaces, and policies remains the single biggest driver of delayed diagnosis and untreated infection.
India's biotechnology and pharmaceutical sectors are positioned to accelerate development and scale-up of new drugs, vaccines, and diagnostics. The government's commitment to the elimination vision appears unwavering. Yet public health officials acknowledge a hard truth: the last mile of an epidemic is always the hardest. It is not purely a problem of medicine. It is social, digital, behavioral, and structural. NACP-VI attempts to address all of those dimensions at once—a strategy that is technologically modern, epidemiologically precise, and grounded in the realities of how people actually live. Whether India can execute that vision at scale, and whether it can do so quickly enough to meet the 2030 deadline for ending AIDS as a public health threat, remains the central question.
Citas Notables
The virus has adapted. It affects those younger, is more dispersed, and exploiting newer vulnerabilities.— Hekali Zhimomi, Additional Secretary and Director General, National AIDS Control Organization
Stigma is the single biggest driver of invisibility, delayed diagnosis and untreated infection.— NACO analysis in NACP Phase-VI strategy
Quieres la nota completa?
Lee el original en The Hindu ↗
Health & Medicine